Topical κ-opioid receptor agonist asimadoline improves dermatitis in a canine model of atopic dermatitis.

Abstract

This prospective, 4-week, placebo-controlled, cross-over study aimed to investigate the efficacy of 1% topical &#x3ba;-opioid agonist, asimadoline, in a model of canine atopic dermatitis (AD). Fourteen beagles were challenged with house dust mites every 3-4&#xa0;days for a total of 9 challenges. Severity of dermatitis was assessed, and pruritus was monitored using GoPro HERO cameras. Pruritus scoring was evaluated at 10 time periods; baseline, 4&#xa0;h post allergen challenge and the last day of the study on Day 28. Scoring was done blindly by personnel using BORIS software. A global subjective score was also given using a visual analogue scale (VAS). A 4-week washout period occurred and dogs were crossed-over, the study was repeated, and the results were analysed using combined data. Gel was applied once daily on inguinal area (0.6&#xa0;ml/dog). ANOVA showed significant effect of time (p&#xa0;<&#xa0;0.0001) and group (p&#xa0;=&#xa0;0.0001) on dermatitis scores. Overall, no statistically significant effect on pruritus was found due to a crossing of scores on Day 17. Overtime the placebo scores increased while the active ingredient showed decrease after first 3&#xa0;weeks. It is concluded that this approach is promising in dogs with AD and longer studies with more frequent application may be beneficial.